Knight Therapeutics Inc (GUD.TO) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA4990531069
Knight Therapeutics Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 371.00 m CAD | 450.09 m CAD |
| Gross profit | 174.00 m CAD | 207.70 m CAD |
| Operating income | – | -2.35 m CAD |
| EBIT | 7.00 m CAD | – |
| Net income | 4.33 m CAD | -5.37 m CAD |
| Diluted EPS – continuing operations | 0.04 CAD | -0.05 CAD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
More stocks
- Guizhou Chitianhua Co Ltd (600227.SS)
- Zbit Semiconductor Inc. A (688416.SS)
- Zhejiang Goldensea Envi Tech C (603311.SS)
- Mader Group Ltd (MAD.AX)
- Caisse Regionale de Credit Agricole Mutuel de Normandie Seine SC (CCN.PA)
- Sinostone Guangdong Co Ltd (001212.SZ)
- Jinxin Fertility Group Ltd (1951.HK)
- Channel Infrastructure Nz Limited (CHI.AX)
- STURM RUGER & CO INC (RGR)
- HILLS BANCORPORATION (HBIA)
- Beken Corp (603068.SS)
- Zenner Metering Technology (Shanghai) Ltd. A (301303.SZ)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.